BrainScope Revenue and Competitors

Claim your profile



Growjo Ranking

Estimated Revenue & Valuation

  • BrainScope's estimated annual revenue is currently $15.1M per year.(i)
  • BrainScope received $16.0M in venture funding in August 2017.
  • BrainScope's estimated revenue per employee is $251,000
  • BrainScope's total funding is $87.1M.

Employee Data

  • BrainScope has 60 Employees.(i)
  • BrainScope grew their employee count by 18% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

BrainScope® is a medical neurotechnology company that is pioneering the assessment of brain injury, including concussion. The company's innovative BrainScope One system is an easy-to-use, non-invasive, hand-held platform that empowers physicians to quickly make accurate head injury assessments at the point-of-care. The benefits could include diversion from the emergency department (ED), a major reduction in unnecessary CT scans, and early intervention for patients with functional injuries, including concussioncontributing to the best possible outcomes in the shortest possible time. Results from clinical studies utilizing BrainScope's technology have been independently published through 24 articles in leading peer-reviewed neurotrauma and emergency medicine journals. BrainScope has been awarded more than $32 million of U.S. Department of Defense research contracts for the development of its TBI and concussion assessment technology and has received two awards from GE and the NFL through its Head Health Challenge I. The company has received significant funding from private investors including Revolution (created by AOL co-founder Steve Case), State of Maryland Venture Fund, ZG Ventures, Brain Trust Accelerator Fund, Difference Capital and DBL Partners. BrainScope holds over 100 issued and pending global patents.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





BrainScope News

2019-05-06 - Over 30% Reduction in Unnecessary Head CT Scans When Integrating FDA-Cleared BrainScope One

Use in the Emergency Room demonstrates BrainScope One can reduce patient radiation exposure, decrease use of hospital resources, and shorten throughput times BETHESDA, Md.–(BUSINESS WIRE)–May 6, 2019– BrainScope announced today the publication of a study conducted by physicians at Washington U ...

2021-02-16 - JAMA Highlights Success of BrainScope's EEG-based Concussion Index As Reliable Indicator of Concussion

BETHESDA, Md., Feb. 16, 2021 /PRNewswire/ -- JAMA Network Open has published "Validation of a Machine Learning Brain Electrical Activity-Based Index to Aid in Diagnosing Concussion Among Athletes," a ground-breaking study on the accuracy of the BrainScope FDA-cleared biomarker, the Concussion ...

2021-03-23 - BrainScope Launches Next-Gen Medical Device: First and only FDA-cleared system for true point-of-care assessment of both concussion and brain bleeds now includes Concussion Index

BETHESDA, Md., March 23, 2021 /PRNewswire/ -- BrainScope today announced the availability of its third groundbreaking FDA-cleared algorithm on the BrainScope device. The Concussion Index is the first physiological marker of concussive injury that aids clinicians in the objective assessment of ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

BrainScope Funding

DateAmountRoundLead InvestorsReference
2017-08-31$16.0MUndisclosedDBL PartnersArticle